Oral Small Molecule for Thyroid Eye Disease

Sling Therapeutics is focused on developing innovative therapies for thyroid eye disease (TED) and other conditions, with a strong emphasis on patient-centered care and scientific rigor in clinical development. Their lead product, linsitinib, is an oral small molecule currently in a Phase 2b clinical trial specifically targeting TED. This therapy works by inhibiting the insulin-like growth factor 1 receptor (IGF-1R), a validated target in the treatment of this condition. Linsitinib has already demonstrated a safety profile through its administration to over 800 patients, indicating its potential for broader applications in treating autoimmune and rare diseases.

In addition to its primary focus on TED, Sling Therapeutics aims to expand its pipeline to provide more treatment options for patients in the fields of ophthalmology, endocrinology, and rare diseases. The company is committed to collaboration with other stakeholders in the healthcare community to enhance the development and accessibility of its therapies. By leveraging their experienced team of executives and scientific advisors, Sling Therapeutics is dedicated to advancing impactful clinical solutions that prioritize patient needs and outcomes.

United States

We are a clinical-stage biopharmaceutical company developing an oral small molecule for the treatment of thyroid eye disease (TED). Our team consists of highly experienced drug developers, supplemented by global experts through our Scientific Advisory Board.

Sling Therapeutics

Company Details